← Back to Search

Anti-inflammatory agent

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

Phase 2
Waitlist Available
Led By Lon Lynn, DO
Research Sponsored by MyMD Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 (8-24 hours post dose)

Summary

This trial tests MYMD1, a drug aimed at reducing inflammation, in older adults with muscle weakness and frailty. The drug works by lowering the chemicals that cause inflammation, potentially improving muscle strength.

Eligible Conditions
  • Frailty
  • Sarcopenia
  • Aging

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 (8-24 hours post dose)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 (8-24 hours post dose) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Capsule (pharmacologic)
Capsule (pharmacologic)
Secondary study objectives
Incidence of Treatment-Emergent Adverse Events

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Cohort 3: MYMD1 900mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 900mg cohort
Group II: Cohort 2: MYMD1 750mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 750 cohort
Group III: Cohort 1: MYMD1 600mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 600mg cohort
Group IV: Cohort 4: MYMD1 1050mgActive Control1 Intervention
Subjects randomly assigned to the MYMD1 1050mg cohort
Group V: Cohort 3: Placebo 900mgPlacebo Group1 Intervention
Subjects assigned to the 900mg placebo group
Group VI: Cohort 4: Placebo group 1050mgPlacebo Group1 Intervention
Subjects assigned to the 1050mg placebo group
Group VII: Cohort 2: Placebo 750mgPlacebo Group1 Intervention
Subjects assigned to the 750mg placebo group
Group VIII: Cohort 1: Placebo 600mgPlacebo Group1 Intervention
Subjects assigned to the 600mg placebo group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYMD-1 900mg
2022
Completed Phase 2
~40
MYMD-1 750mg
2022
Completed Phase 2
~40
MYMD-1 600MG
2022
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

MyMD Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
Lon Lynn, DOPrincipal InvestigatorClinical Research of West Florida
Leonard Dunn, MDPrincipal InvestigatorClinical Research of West Florida
3 Previous Clinical Trials
1,743 Total Patients Enrolled
Jeremy Walston, MDPrincipal InvestigatorJohns Hopkins University
2 Previous Clinical Trials
48 Total Patients Enrolled
~10 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top